A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia

Clinical trial NCT06853444 · RECRUITING

Trial details

NCT number: NCT06853444
Sponsor: Shanghai Escugen Biotechnology Co., Ltd
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Immune Thrombocytopenia (ITP)

Start date: 2025-05-08
Primary completion: 2026-03-31
Enrollment: 84

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.